<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl0003">
 <label>Table 3</label>
 <caption>
  <p>Alternative assumptions used for the risk of death experienced by those PLHIV whose ART supply is interrupted.</p>
 </caption>
 <alt-text id="alt0006">Table 3</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th valign="top"/>
    <th valign="top">
     <italic>Average monthly mortality risk</italic>
    </th>
    <th valign="top">
     <italic>Proportion that would die after one year</italic>
    </th>
    <th valign="top">
     <italic>Justification</italic>
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td valign="top">
     <italic>Lower bound</italic>
    </td>
    <td valign="top">0.10%</td>
    <td valign="top">1.24%</td>
    <td valign="top">This is a hypothetical best-case scenario in which the vast majority of individuals do not deteriorate rapidly.</td>
   </tr>
   <tr>
    <td valign="top">
     <italic>Medium</italic>
    </td>
    <td valign="top">0.24%</td>
    <td valign="top">2.91%</td>
    <td valign="top">The SMART trial found a 3% risk at 12 months of either death of an opportunistic infection for those with interrupted ART 
     <xref rid="bib0013" ref-type="bibr">[13]</xref>. This also implies a mean survival time approximately equivalent to that for HIV-positive persons who have never been on ART 
     <xref rid="bib0014" ref-type="bibr">[14]</xref>.
    </td>
   </tr>
   <tr>
    <td valign="top">
     <italic>Upper bound</italic>
    </td>
    <td valign="top">0.44%</td>
    <td valign="top">5.28%</td>
    <td valign="top">This is the hypothetical worst-case scenario in which many persons deteriorate more rapidly.</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
